Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313242169> ?p ?o ?g. }
- W4313242169 endingPage "1374" @default.
- W4313242169 startingPage "1365" @default.
- W4313242169 abstract "Programmed cell death-ligand 2 (PD-L2) is an important emerging molecule of the immune checkpoint, which is closely related to the prognosis of patients with immune checkpoint inhibitor (ICI) therapy. The quantification of PD-L2 can provide a potential reference for patients who benefit from ICI treatment. In this study, we used iodine isotope (nat/124/125I)-labeled PD-L2 antibody (ATL2) to noninvasively detect PD-L2 expression in mice with human lung adenocarcinoma A549 cell lines. The radiochemical yields of 125I-ATL2 and 124I-ATL2 were 73.56 ± 3.72% and 69.46 ± 2.05%, respectively. The radiochemical purity (RCP) of the tracers was more than 99%. The positive cell line A549-PDL2 was constructed by lentivirus. Western blot, immunofluorescence, and flow cytometry indicated that the A549-PDL2 cells showed a higher PD-L2 protein level than the A549 cells. The dissociation constant of 125I-ATL2 binding to the PD-L2 protein was 7.25 nM. Cellular uptake experiments confirmed that the uptake of 125I-ATL2 in A549-PDL2 cells was higher than that in A549 cells at each time point (P < 0.0001). Micro-PET/CT showed significant uptake in the tumor region of A549-PDL2 tumor-bearing mice 24 h postinjection of 124I-ATL2 compared with that of other groups (SUVmax = 0.75 ± 0.06, 0.19 ± 0.07, and 0.27 ± 0.05, respectively). Consistently, the biodistribution of the tracers at 24 h postinjection showed a higher tumor uptake in A549-PDL2 mice (7.11 ± 0.38 %ID/g for 124I-ATL2 in A549-PDL2 mice vs 2.72 ± 0.15 %ID/g for 124I-ATL2 in A549 mice vs 3.89 ± 0.65 %ID/g for 124I-IgG in A549-PDL2 mice). The dosimetry estimation by using Olinda software showed that the effective dose of 124I-ATL2 was 3.62 × 10-2 mSv/MBq, which is within the range of acceptable doses. Immunohistochemical results further confirmed that the expression of PD-L2 in the tumor tissues of A549-PDL2-bearing mice was higher than that of the A549 model mice. In conclusion, the development of 124/125I-ATL2 provides the first noninvasive quantification of PD-L2 expression in lung cancer by molecular imaging, which provides a new reference for screening potential beneficiaries of ICI therapy." @default.
- W4313242169 created "2023-01-06" @default.
- W4313242169 creator A5014295844 @default.
- W4313242169 creator A5019005904 @default.
- W4313242169 creator A5023005054 @default.
- W4313242169 creator A5038609647 @default.
- W4313242169 creator A5048800314 @default.
- W4313242169 creator A5053846840 @default.
- W4313242169 creator A5057270408 @default.
- W4313242169 creator A5067981325 @default.
- W4313242169 creator A5070131847 @default.
- W4313242169 creator A5072800407 @default.
- W4313242169 creator A5077643542 @default.
- W4313242169 creator A5085414566 @default.
- W4313242169 creator A5091383290 @default.
- W4313242169 date "2022-12-29" @default.
- W4313242169 modified "2023-09-27" @default.
- W4313242169 title "Construction and Preclinical Evaluation of a <sup>124/125</sup>I-Labeled Specific Antibody Targeting PD-L2 in Lung Cancer" @default.
- W4313242169 cites W1982488143 @default.
- W4313242169 cites W2107752337 @default.
- W4313242169 cites W2605045407 @default.
- W4313242169 cites W2606721249 @default.
- W4313242169 cites W2783173849 @default.
- W4313242169 cites W2794621764 @default.
- W4313242169 cites W2893960509 @default.
- W4313242169 cites W2901272595 @default.
- W4313242169 cites W2944181742 @default.
- W4313242169 cites W2948046941 @default.
- W4313242169 cites W2949515538 @default.
- W4313242169 cites W2984538501 @default.
- W4313242169 cites W3007091255 @default.
- W4313242169 cites W3013675046 @default.
- W4313242169 cites W3016210953 @default.
- W4313242169 cites W3117706403 @default.
- W4313242169 cites W3122516621 @default.
- W4313242169 cites W3128131226 @default.
- W4313242169 cites W3132841322 @default.
- W4313242169 cites W3145244707 @default.
- W4313242169 cites W3161620475 @default.
- W4313242169 cites W3181187261 @default.
- W4313242169 cites W3183336980 @default.
- W4313242169 cites W4206841660 @default.
- W4313242169 cites W4210918042 @default.
- W4313242169 doi "https://doi.org/10.1021/acs.molpharmaceut.2c00958" @default.
- W4313242169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36579764" @default.
- W4313242169 hasPublicationYear "2022" @default.
- W4313242169 type Work @default.
- W4313242169 citedByCount "0" @default.
- W4313242169 crossrefType "journal-article" @default.
- W4313242169 hasAuthorship W4313242169A5014295844 @default.
- W4313242169 hasAuthorship W4313242169A5019005904 @default.
- W4313242169 hasAuthorship W4313242169A5023005054 @default.
- W4313242169 hasAuthorship W4313242169A5038609647 @default.
- W4313242169 hasAuthorship W4313242169A5048800314 @default.
- W4313242169 hasAuthorship W4313242169A5053846840 @default.
- W4313242169 hasAuthorship W4313242169A5057270408 @default.
- W4313242169 hasAuthorship W4313242169A5067981325 @default.
- W4313242169 hasAuthorship W4313242169A5070131847 @default.
- W4313242169 hasAuthorship W4313242169A5072800407 @default.
- W4313242169 hasAuthorship W4313242169A5077643542 @default.
- W4313242169 hasAuthorship W4313242169A5085414566 @default.
- W4313242169 hasAuthorship W4313242169A5091383290 @default.
- W4313242169 hasConcept C104317684 @default.
- W4313242169 hasConcept C1491633281 @default.
- W4313242169 hasConcept C153911025 @default.
- W4313242169 hasConcept C159654299 @default.
- W4313242169 hasConcept C185592680 @default.
- W4313242169 hasConcept C202751555 @default.
- W4313242169 hasConcept C203014093 @default.
- W4313242169 hasConcept C2776415932 @default.
- W4313242169 hasConcept C2777701055 @default.
- W4313242169 hasConcept C2777807558 @default.
- W4313242169 hasConcept C2781053074 @default.
- W4313242169 hasConcept C502942594 @default.
- W4313242169 hasConcept C54355233 @default.
- W4313242169 hasConcept C553184892 @default.
- W4313242169 hasConcept C55493867 @default.
- W4313242169 hasConcept C81729549 @default.
- W4313242169 hasConcept C81885089 @default.
- W4313242169 hasConcept C86803240 @default.
- W4313242169 hasConcept C8891405 @default.
- W4313242169 hasConceptScore W4313242169C104317684 @default.
- W4313242169 hasConceptScore W4313242169C1491633281 @default.
- W4313242169 hasConceptScore W4313242169C153911025 @default.
- W4313242169 hasConceptScore W4313242169C159654299 @default.
- W4313242169 hasConceptScore W4313242169C185592680 @default.
- W4313242169 hasConceptScore W4313242169C202751555 @default.
- W4313242169 hasConceptScore W4313242169C203014093 @default.
- W4313242169 hasConceptScore W4313242169C2776415932 @default.
- W4313242169 hasConceptScore W4313242169C2777701055 @default.
- W4313242169 hasConceptScore W4313242169C2777807558 @default.
- W4313242169 hasConceptScore W4313242169C2781053074 @default.
- W4313242169 hasConceptScore W4313242169C502942594 @default.
- W4313242169 hasConceptScore W4313242169C54355233 @default.
- W4313242169 hasConceptScore W4313242169C553184892 @default.
- W4313242169 hasConceptScore W4313242169C55493867 @default.
- W4313242169 hasConceptScore W4313242169C81729549 @default.
- W4313242169 hasConceptScore W4313242169C81885089 @default.